|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Through dual‑luciferase reporter gene assay and functional experiments, the potential functions of circ‑FAM53B/miRNA‑646/vesicle‑associated membrane protein 2 (VAMP2) and circ‑FAM53B/miRNA‑647/mouse double minute 2 (MDM2) in mediating the progression of OC were identified.
|
31638250 |
2019 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
CXCR2 is a negative regulator of p21 in p53-dependent and independent manner via Akt-mediated Mdm2 in ovarian cancer.
|
29515768 |
2018 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
These data indicate that combination treatment with MDM2 inhibitors and rucaparib has synergistic and dose reduction potential for the treatment of ovarian cancer, dependent on cell type.
|
29050241 |
2017 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study suggests that MDM2 activates Smad pathway to promote EMT in ovarian cancer metastasis, and targeting the N-terminal of MDM2 can reprogram EMT and impede the mobility of cancer cells.
|
28817834 |
2017 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This meta-analysis provides evidence for the association between MDM2 309 polymorphism and ovarian cancer risk, supporting the hypothesis that MDM2 SNP309 G allele acts as an important ovarian cancer protective factor in Asians but not in Caucasians.
|
23383041 |
2013 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A possible functional impairment of the p53 pathway caused by the G/G genotype of the MDM2 SNP309 may modify the association between p53 mutational status and prognosis in ovarian cancer.
|
22134502 |
2012 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We explored the distribution of the MDM2 polymorphisms SNP309T>G and the recently discovered SNP285G>C in Norwegian patients with BRCA related ovarian cancer.
|
23039163 |
2012 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The MDM2 promoter SNP285C/309G haplotype diminishes Sp1 transcription factor binding and reduces risk for breast and ovarian cancer in Caucasians.
|
21316605 |
2011 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
We further investigated the expression and mutation of Tp53 and associated markers such as p21 and HDM2 in ovarian cancer.
|
19375154 |
2009 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although MDM2 Del1518+/- genotypes and allele frequencies did not differ between the case and the control groups (P = 0.68 and P = 0.45), Del1518 +/+ genotype tended to increase the risk of mucinous ovarian cancer or earlier ovarian cancer by stratification analysis according to histological subtypes or clinical stage.
|
19509552 |
2009 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
The blockage of the MAPK/ER/MDM2 pathway suppress cell proliferation and it is supposed as a new molecular target therapy in estrogen-dependent gynecologic cancers, such as endometrial or ovarian cancer.
|
17306348 |
2007 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This study has found no evidence that the GG genotype of the MDM2 SNP309 polymorphism is associated with early onset or familial breast cancer or with ovarian cancer.
|
16239061 |
2006 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Immunohistochemical analysis of the proteins encoded by the genes that were amplified frequently (FGF3/4, FGFR1, CCNE1, PAK1, JUNB, and MDM2) was performed on a tissue microarray comprising 254 cases of ovarian neoplasms.
|
16753589 |
2006 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Amplification of 20q is frequently implicated in both breast and ovarian cancer; this region contains a number of oncogenes including MDM2, ZNF217, and the ovarian tumor marker WFDC2 (alias HE4).
|
16080959 |
2005 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
Although heparanase activity seems to play an essential role in tumor progression, expression of oncogenes, such as erbB2 and Mdm2 seems to play the dominant role in the development of ovarian cancer.
|
11351242 |
2001 |
|
ovarian neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, laminin-1 exerts its proliferative effect on the development of ovarian tumors via upregulation of survival genes such as Bcl-2 and Mdm2.
|
11295035 |
2001 |
|
ovarian neoplasm
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
It is amplified or overexpressed in many human cancers, including breast cancer, and MDM2 levels are associated with poor prognosis of several human cancers, including breast cancer, ovarian cancer, osteosarcoma, and lymphoma.
|
11705884 |
2001 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
We conducted a retrospective immunohistochemical evaluation of the prognostic significance of the expression of p53 and the related proteins Bax, Bcl-2, growth arrest and DNA damage (Gadd45), murine double minute 2 (Mdm2) and p21(WAF1/CIP1) in chemonaive tumours taken from 66 patients with ovarian cancer.
|
11094305 |
2000 |
|
ovarian neoplasm
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
It was recently reported that the expression of alternatively spliced variants of mdm2 correlated with malignancy in ovarian tumors and bladder carcinomas.
|
9485008 |
1998 |
|
ovarian neoplasm
|
0.100 |
Biomarker
|
disease |
BEFREE |
We tested 1371 breast and 179 ovarian tumours by Southern blotting and observed amplification of 20q13 in 5.4% breast and 2.8% ovarian carcinomas, whereas MDM2 was found amplified in 5.3% and 3.8% of breast and ovarian tumours respectively.
|
8980401 |
1996 |